Herantis Pharma has announced a publication in Cell Chemical Biology journal.

The title of the publication is HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson’s disease. It summarizes preclinical development data on subcutaneously administered HER-096, including pharmacokinetics and distribution data in rats and mice, and demonstration of therapeutic effects in an aged mouse model of Parkinson’s disease.

This publication demonstrates blood-brain barrier penetration in animals and therapeutic potential of HER-096 in a highly relevant animal model of neurodegeneration.”

“This publication demonstrates blood-brain barrier penetration in animals and therapeutic potential of HER-096 in a highly relevant animal model of neurodegeneration,” says Henri Huttunen, CSO of Herantis Pharma and the senior author of the publication. “Thanks to our network of highly capable drug development experts, both internally and externally, we have been able to advance HER-096 rapidly since the preclinical candidate selection in May 2021.”

Photo: iStock